医渡科技 6 月通讯 | 2024 年

Yidu Tech Events in June 2024

集团亮点

Business Update

医渡科技 2024 财年业绩：毛利率创历史新高，盈利能力持续加强

Yidu Tech FY2024 Results: Gross Profit Margin Hits Record High, Profitability Continues to Improve

中国 AI 医疗头部企业医渡科技（股票代码：2158.HK）发布 2024 财年业绩公告并召开业绩发布会。在‘聚焦’战略下，医渡科技经营效率、盈利能力和业务竞争力均实现了进一步提升。公司 2024 财年总收入为人民币 8.07 亿元，毛利率从去年同期的 34.1%上升至 42.1%，提高 8 个百分点，创下历史新高。经调整净亏损由去年同期的人民币 4.49 亿元收窄至人民币 1.58 亿元，较上年同期大幅减亏 64.8%，现金流持续优化。公司管理层表示，剔除自研大模型的战略性投入、非现金科目、非运营科目后，现有业务管理口径经调整 EBITDA 从去年同期的亏损人民币 3.27 亿由亏转盈，至本财年的首次盈利人民币 3110 万元。

China's AI medical leader Yidu Tech Inc. (stock code: 2158.HK) announced its FY2024 results and held an announcement conference. Under the "Focus" Strategy, Yidu Tech has further enhanced operational efficiency, profitability, and business competitiveness. The Company's total revenue for FY2024 was RMB 807.1 million, and the gross profit margin increased from 34.1% in the previous year to 42.1%, up by 8 percentage points, reaching a record high. The adjusted net loss narrowed from RMB 448.7 million in the previous year to RMB 158.1 million, a significant year-on-year reduction of 64.8%, with cash flow continuously optimized. The management stated that excluding strategic

investments in the proprietary large language model, non-cash items, and non-operating items, the adjusted EBITDA of the existing business has turned around from a loss of RMB 327 million in the previous year to a profit of RMB 31.1 million for the first time in this fiscal year.

宫如璟董事长出席夏季达沃斯论坛，与世界嘉宾共探 AI 医疗新未来

Chairlady Gong Rujing Attends Summer Davos Forum to Explore the Future of AI in Healthcare with Global Guests

在世界经济论坛第十五届新领军者年会（夏季达沃斯论坛）上，医渡科技董事长兼创始人宫如璟女士作为 AI 医疗领域的领军人物、全球青年领袖应邀出席，参加了总理特别座谈会及多场高级别闭门会议，并与多国政商界嘉宾展开了友好交流。在“加速推进数据分析在医疗行业的应用”主题对话中，她表示，要实现医疗数据的巨大潜力，建立信任是关键，同时需要提升数据的可操作性，以充分释放医疗数据的力量。

At the 15th Annual Meeting of the New Champions (Summer Davos Forum) of the World Economic Forum, Ms. Gong Rujing, Chairlady and Founder of Yidu Tech, was invited to attend as a leading figure in the AI medical field and a Young Global Leader. She participated in the Special Session with the Premier and several high-level closed-door meetings, engaging in friendly exchanges with guests from various political and business circles around the world. During the themed dialogue on "Healthcare Analytics, Not Moving Fast Enough," she emphasized that establishing trust is crucial to realizing the potential of medical data, and that enhancing the operability of data is essential to fully unleash the power of medical data.

医渡科技大模型通过国家网信办算法备案

Yidu Tech's Large Language Model Passes Algorithm Filing by the Cyberspace Administration of China

根据国家互联网信息办公室发布的第四批深度合成服务算法备案信息，医渡科技大模型已成功通过算法备案，标志着其技术实力以及算法的安全性、合规性获得了国家级权威认可。

According to the fourth batch of deep synthesis service algorithm filing information released by the Cyberspace Administration of China, Yidu Tech's large language model (LLM) has successfully passed the algorithm filing, marking national-level authoritative recognition of its technical strength as well as the safety and compliance of its algorithms.

医渡科技出席首届中国大模型大会

Yidu Tech Attends the First China Large Language Model Conference

医渡科技 CTO、首席人工智能科学家闫峻博士作为医疗大模型实践代表出席“大模型+

医疗健康”专题论坛，发表了“医疗垂直领域大模型的建设与应用”主题演讲，指出大模型是多任务引擎，为了进一步发挥大模型的多任务引擎价值，医渡科技将原有的医疗数据中台与大模型赋能的医疗 AI 中台相结合，形成医院数据智能双中台底座，赋予医院自主创新能力。

Dr. Yan Jun, CTO and Chief AI Scientist of Yidu Tech, attended the "Large Language Model + Medical Health" forum as a representative of medical LLM practice. He delivered a keynote speech on "The Construction and Application of LLMs in the Medical Vertical Field," pointing out that LLMs serve as multi-task engines. To further leverage the value of these engines, Yidu Tech has integrated its existing medical data platform with the AI-empowered medical platform, forming a dual-platform foundation of hospital data intelligence that empowers hospitals with autonomous innovation capabilities.

医渡科技出席首届全球医疗科技大会

Yidu Tech Attends the First Global Medical Technology Conference

首届全球医疗科技大会与全球生物医药大会在北京召开。医渡科技 CTO、首席人工智能科学家闫峻受邀发表“医疗垂域大模型的建设及应用方向”主题演讲，详细介绍了医渡

科技在医疗大模型建设方面的探索和实践。医渡科技大模型已与北京大学肿瘤医院、北京儿童医院等多家医院合作，在医院科研、临床诊疗以及临床试验等场景中探索落地。

The First Global Medical Technology Conference and the Global Biopharma Conference were held in Beijing. Dr. Yan Jun, CTO and Chief AI Scientist of Yidu Tech, was invited to deliver a keynote speech on "The Construction and Application Directions of LLMs in the Medical Vertical Field," detailing Yidu Tech's exploration and practice in building medical LLM. Yidu Tech's LLM have been applied in collaboration with hospitals such as Peking University Cancer Hospital and Beijing Children's Hospital, exploring applications in scenarios including hospital research, clinical diagnosis, and clinical trials.

医渡科技与华为联合启动 AI 原生应用引擎全域生态合作

Yidu Tech and Huawei Jointly Launch Comprehensive AI Native Application Engine Ecosystem Collaboration

华为开发者大会 2024(HDC 2024)期间，医渡科技受邀出席，并参与“AI 原生应用引擎全域生态合作启航仪式”。 这一合作标志着双方将进一步深化在 AI 医疗领域的合作，共同推动 AI 原生应用引擎在医疗健康领域的广泛应用。此前，双方已经建立了深入的

合作关系，并携手发布了智慧医疗联合解决方案和医渡科技大模型训推一体机解决方案等创新产品。

During the Huawei Developer Conference 2024 (HDC 2024), Yidu Tech was invited to attend and participate in the launch ceremony of the "AI Native Application Engine Ecosystem Collaboration." This partnership marks a further deepening of cooperation between the two parties in the AI medical field, jointly promoting the widespread application of the AI Native Application Engine in healthcare. Previously, the two parties have established an in-depth cooperative relationship and jointly released innovative products such as the Smart Healthcare Joint Solution and Yidu Tech's LLM Training and Inference Integrated Solution.

医渡科技出席滨海中关村协同创新发展交流会

Yidu Tech Attends the Binhai Zhongguancun Collaborative Innovation Development Exchange Meeting

以“协同创新 智启未来”为主题的第三届滨海中关村协同创新发展交流会在北京成功举办。医渡科技旗下医渡云政府和公共卫生事业部总经理李继刚先生受邀出席以“数字

化赋能驱动生命健康产业发展”为主题的圆桌对话，他表示，人工智能等数字化技术可以提高医疗服务的效率和质量、促进医疗科研的创新和发展，以及在全民健康、监管服务、个人健康管理等多场景中深度应用。

The third Binhai Zhongguancun Collaborative Innovation Development Exchange Meeting, themed "Collaborative Innovation, Intelligent Future," was successfully held in Beijing. Mr. Li Jigang, General Manager of YiduCloud's Government and Public Health Division, a subsidiary of Yidu Tech, was invited to participate in a roundtable dialogue themed "Digital Empowerment Driving the Development of the Life and Health Industry." He stated that digital technologies such as artificial intelligence can improve the efficiency and quality of healthcare services, promote innovation and development in medical research, and be deeply applied in various scenarios including public health, regulatory services, and personal health management.

业务进展

Business Progress

HLT 中标眼科领域某细胞疗法临床试验 CRO 服务项目

HLT Wins Bid for Clinical Trial CRO Services Project for an Ophthalmic Cell Therapy

HLT 将为某细胞治疗药物研发公司针对 RP 患者的临床试验项目提供 CRO 服务。该项目是 HLT 在眼科领域的又一次重要突破，也是与该客户的再次合作。HLT 凭借其在眼科领域的专业素养和丰富经验，以及在项目中的出色表现，赢得了客户继续合作的信心。

HLT will provide CRO services for a clinical trial project targeting RP patients on behalf of a cell therapy drug development company. This project marks another significant breakthrough for HLT in the ophthalmology field and represents a renewed collaboration with this client. HLT has earned the client's confidence to continue the partnership through its professional expertise and extensive experience in ophthalmology, as well as its outstanding performance in previous projects.

HLT 中标某治疗轻中度阿尔茨海默病药物 CRO 服务项目

HLT Wins Bid for CRO Services Project for a Drug Treating Mild to Moderate Alzheimer's Disease

该客户是一家创新生物技术公司，HLT 在与其之前的合作中，通过稽查、数统等专业服务赢得客户信任，得以促成再次合作。阿尔兹海默症是人类全球性健康挑战，目前尚无治愈药物，本次 HLT 将深度参与阿尔兹海默症的药品研究，为推动神经疾病治疗的发展做出积极贡献。

The client, an innovative biotechnology company, has once again chosen to collaborate with HLT following their previous successful partnership, which included services such as audits and statistical analysis. Alzheimer's disease is a global health challenge with no cure currently available. This time, HLT will deeply engage in the

drug research for Alzheimer's disease, making a positive contribution to the development of treatments for neurological diseases.

HLT 助力特应性皮炎关键性Ⅲ期临床研究开展，已完成首例受试者入组

HLT Supports Key Phase III Clinical Study of Atopic Dermatitis, Has Completed First Subject Enrolled

该项目旨在评估某药物在治疗特应性皮炎中的疗效及安全性。HLT 在皮肤领域拥有丰富的项目经验，此次推进特应性皮炎关键性项目开展，是强化皮肤领域布局的重要一步。HLT 基于持续构建的坚实临床研究平台网络体系，通过更加精准的患者人群与疾病适应症定位，优化的临床研究设计，制定高效运营策略，在保证临床试验质量基础上，全面推进项目高效开展，加速药物在国内上市进程，目前已完成首例受试者入组。

This project aims to evaluate the efficacy and safety of a drug in treating atopic dermatitis. With extensive project experience in the dermatology field, HLT's advancement of this key atopic dermatitis project is a crucial step in strengthening its presence in dermatology. HLT is leveraging its robust clinical research platform network, precise patient population, and disease indication targeting, optimized clinical research design, and efficient operational strategies to ensure high-quality and efficient project execution. The first subject has already been enrolled, accelerating the drug's progress towards market approval in China.

医渡云中标安徽省某头部三甲医院临床数据中心项目

Yidu Cloud Wins Bid for Clinical Data Center Project at a Leading Tertiary Hospital in Anhui Province

该项目旨在为该院构建一个基于分布式架构的基础医疗大数据平台，并依托该平台完成医疗数据治理、数据资产管理，为临床、运营、科研等各类应用提供全方位支撑，从而

驱动医院智能化转型升级。此次中标进一步巩固了医渡云在华东区域的市场地位，也为公司未来在安徽的业务发展奠定了坚实基础。

This project aims to construct a foundational medical big data platform based on a distributed architecture for the hospital. The platform will support comprehensive medical data governance and data asset management, providing all-round support for clinical, operational, and research applications, thereby driving the hospital's intelligent transformation and upgrading. This successful bid further consolidates Yidu Cloud's market position in the East China region and lays a solid foundation for future business development in Anhui.

医渡云中标北京某三甲医院研究型病房科研数据中心建设项目

Yidu Cloud Wins Bid for Research Data Center Construction Project at a Tertiary Hospital in Beijing

该院是首批国家精神病临床重点专科单位，国家药物临床试验机构。此次中标医渡云将助力该院建设研究型病房科研数据中心。这将进一步提高医院的临床研究能力，并为双方的后续合作创造更多可能。

The hospital is among the first nationally recognized clinical key specialty units for psychiatry and a national drug clinical trial institution. This successful bid enables Yidu Cloud to assist the hospital in constructing a research data center for its research wards. This will significantly enhance the hospital's clinical research capabilities and create more opportunities for future cooperation between the two parties.

医渡云专病库助力中山大学肿瘤防治中心研究成果发表于《柳叶刀》

Yidu Cloud's Disease Database Supports Research Results Published in The Lancet by Sun Yat-sen University Cancer Center

中山大学肿瘤防治中心马骏院士牵头联合华中科技大学同济医学院附属协和医院等9家单位，合作完成的研究成果在线发表于国际顶尖医学期刊《柳叶刀》（Lancet，IF：169分）。医渡云建立的大数据科研平台和专病库为该研究提供了强大的技术支持，对研究的顺利开展起到了重要作用。医渡云与中山大学肿瘤防治中心已成功部署并应用了包括新一代数据中心、肿瘤专科大数据平台、全瘤种科研平台及鼻咽癌专病数据库在内的多个数据平台。这些平台全方位支持了医院的智慧临床实践、科研创新、高效管理和智慧服务，成为驱动医院高质量发展的核心引擎。

A research study led by Academician Ma Jun of Sun Yat-sen University Cancer Center, in collaboration with nine institutions including Union Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology, was published online in the top international medical journal The Lancet (IF: 169). The big data research platform and disease database established by Yidu Cloud provided robust technical support for the research, playing a critical role in its successful completion. Yidu Cloud and Sun Yat-sen University Cancer Center have successfully deployed and applied multiple data platforms, including the next-generation data center, oncology big data platform, comprehensive cancer research platform, and nasopharyngeal carcinoma disease database. These platforms comprehensively support the hospital's smart clinical practices, research innovation, efficient management, and intelligent services, driving high-quality development as a core engine.



the medical, nursing, and research staff at each study centre. We also thank Qiu-Hui Zheng, Ling Jin, Juan Liu, and Hui-Xia Feng (Department of Radiation Oncology, SYSUCC, Guangzhou, China) for assistance with the data management and logistic support. We thank the National Clinical Study Center for anticancer drugs and SYSUCC for trial monitoring and data management. We thank Yiducloud (Beijing) Technology for the establishment of the big data intelligence platform at SYSUCC, and Shu-Yi Zheng from Yiducloud for assistance during data management. We thank Yexiong Li (Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China), Brian O'Sullivan (Princess Margaret Cancer Centre, Toronto, ON, Canada), and Ying Guo (SYSUCC) for their contribution as members of the independent data

医渡科技
YIDUTECH

医渡云承建的“江苏省中医院科研数据中心”项目正式启动

Yidu Cloud’s "Research Data Center of Jiangsu Provincial TCM Hospital" Project Officially Launched

此次合作率先形成了国内中医院高质量全院级科研平台的建设，旨在助力江苏省中医院开辟一条中医药科技创新的新赛道。该项目还将依托科研数据平台将对高血压、肺癌、胃癌重点疾病进行深入符合中医药特点及国际规范的临床疗效评价研究。

This collaboration marks the first high-quality, full-hospital research platform construction for a TCM hospital in China. It aims to help Jiangsu Provincial TCM Hospital open a new path for TCM technology innovation. The project will leverage the research data platform to conduct in-depth clinical efficacy evaluation studies on key diseases such as hypertension, lung cancer, and gastric cancer, in line with TCM characteristics and international standards.

集团荣誉

Honors of Yidu Tech

医渡云与中肿联合申报案例获评“2024 医院新兴技术创新应用典型案例”

Yidu Cloud and Sun Yat-sen University Cancer Center Joint Application Recognized as a "2024 Emerging Technology Innovation Application Case"

由中山大学肿瘤防治中心牵头，医渡科技旗下医渡云联合申报的《“1+N+X”肿瘤专科大数据平台纵深应用赋能智慧医院高质量发展》案例，成功入选 2024 医院新兴技术创新应用典型案例。医渡云助力中肿建立了全院级大数据平台及全瘤种数据平台，目前已建成 42 个专科专病库，建立多个瘤种数据标准，其中结直肠癌、鼻咽癌已发布标准数据集。

The case study titled “In-Depth Application of the ‘1+N+X’ Oncology Big Data Platform

Empowering High-Quality Development of Smart Hospitals," jointly submitted by Yidu Cloud under Yidu Tech and led by Sun Yat-sen University Cancer Center, has been selected as a "2024 Emerging Technology Innovation Application Case." Yidu Cloud has assisted the cancer center in establishing a comprehensive hospital-level big data platform and an all-cancer data platform, currently comprising 42 specialized disease databases. Multiple cancer data standards have been established, with standardized datasets for colorectal cancer and nasopharyngeal carcinoma already published.

HLT 获 CphMRA 年会双项荣誉，市场洞察创新实力备受肯定

HLT Receives Double Honors at CphMRA Annual Meeting, Market Insight Innovation Strength Highly Recognized

作为生命科学创新解决方案的排头兵及 CphMRA 的老朋友，医渡科技旗下开心生活科技（HLT）受邀出席大会，并荣获“AI+创新解决方案领先供应商”称号。同时，HLT 申报的“ChatGPT 驱动的市场洞察与卓越产品上市策略”项目，成功入选“AI+医药创新前瞻案例”榜单，体现了业界对 HLT 技术创新实力的高度认可。

As a pioneer in life science innovation solutions and a long-time partner of CphMRA, Happy Life Tech (HLT) under Yidu Tech was invited to attend the conference and was awarded the title of "Leading Supplier of AI+ Innovative Solutions." Additionally, HLT's project "ChatGPT-Driven Market Insights and Superior Product Launch Strategies" was successfully selected for the "AI+ Pharmaceutical Innovation Forward-Looking Case" list, showcasing the industry's high recognition of HLT's technological innovation capabilities.

资本市场动态

Capital Market Dynamics

花旗、中金、光大维持医渡科技买入评级

Citi, CICC, and Everbright Maintain Buy Rating on Yidu Tech

医渡科技公布 2024 财年业绩后，花旗、中金、光大海外多家投行机构接连发布研报对其维持“买入”评级。其中，花旗给出了 8 港元的目标价。光大在报告中指出，大数据平台解决方案板块收入同比回升，AI 医疗大脑 YiduCore 加速迭代，生命科学解决方案板块收入同比上升，中长期市占率有望提升。中金表示，医渡科技聚焦核心业务，专注提升经营效率和盈利质量，持续投入 AI，给予医渡科技维持跑赢行业评级和目标价 5.8 港元。

Following the announcement of Yidu Tech's FY2024 results, multiple investment banks including Citi, CICC, and Everbright Overseas have consecutively released research reports maintaining their "Buy" ratings on the company. Citi provided a target price of HKD 8. Everbright highlighted in its report that revenue from the big data platform solutions segment rebounded year-on-year, the AI medical brain YiduCore accelerated its iterations, and the life sciences solutions segment saw a year-on-year increase in revenue, with the potential for long-term market share growth. CICC noted that Yidu Tech is focusing on its core business, striving to improve operational efficiency and profitability, and continuing its investment in AI, maintaining an outperform rating and a target price of HKD 5.8.